Inhibitors of CDK4/6 have been shown to have significant activity against several solid tumors, increase intracellular double-stranded RNA levels, and activate endogenous retroviral elements to inhibit tumor cell expression (Goel et al., 2017). Here, CDK4 is linked to neoplasm.